Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236299 | 0.82 | DRD2 (0.62) | DRD2ADRA1ADRD4DRD3MEN1 | |
| SCHEMBL10287607 | 0.81 | OPRM1 (0.63) | DRD2ADRA1ACCR1DRD3HTR1A | |
| SCHEMBL14307260 | 0.79 | CCR3 (0.69) | DRD2ADRA1ACCR1DRD3HTR1A | |
| SCHEMBL11632873 | 0.79 | ALDH1A1 (0.56) | DRD2DRD4MEN1CYP1A2CYP3A4 | |
| SCHEMBL20254427 | 0.78 | DRD2 (0.74) | DRD2ADRA1ADRD4DRD3MEN1 | |
| SCHEMBL7463924 | 0.78 | CCR3 (0.71) | CCR1 | |
| SCHEMBL11938907 | 0.77 | DRD2 (0.65) | DRD2ADRA1ACCR1DRD3HTR1A | |
| SCHEMBL7467269 | 0.77 | CCR3 (0.68) | CCR1 | |
| SCHEMBL10287975 | 0.76 | CCR3 (0.65) | DRD2ADRA1ACCR1DRD3HTR1A | |
| SCHEMBL3278197 | 0.75 | APP (0.53) | CCR1MEN1OPRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151553-A1 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | US | disclosed |
| US-6433165-B1 | ANTIINFLAMMATORY AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1204640-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6323206-B1 | ANTIINFLAMMATORY AGENTS AND VIRICIDES FOR AIDS WITH CYTOKINESAND CHEMOKINES | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2001009094-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049675-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1047675-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999037617-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999037619-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151553-A1 | Chemokine receptor antagonists and methods of use therefor | CCR1, CCR2, CCR5 | DRD2 2098/4885ADRA1A 445/4885CCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.